| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥482.6B | ¥466.6B | +3.4% |
| Operating Income | ¥23.7B | ¥36.3B | -34.8% |
| Ordinary Income | ¥22.2B | ¥33.4B | -33.7% |
| Net Income | ¥16.8B | ¥24.0B | -29.9% |
| ROE | 4.9% | 7.3% | - |
FY2025 Q3 results show revenue of 482.6B yen (YoY +3.4%) with operating income of 23.7B yen (YoY -34.8%), ordinary income of 22.2B yen (YoY -33.7%), and net income of 16.8B yen (YoY -29.9%). While top-line growth remained steady at +3.4%, profitability deteriorated sharply with operating margin contracting to 4.9% from prior year's 7.8%, a decline of 289 basis points. The profit decline was driven primarily by SG&A expense expansion to 101.5B yen (21.0% of revenue), overshadowing stable gross profit margin of 25.9%. Short-term borrowings surged 46.7% YoY to 276.2B yen, raising liquidity concerns as cash-to-short-term-debt coverage stands at 0.25x with cash and deposits of 68.8B yen.
Revenue increased 3.4% YoY to 482.6B yen, demonstrating continued top-line momentum. Cost of sales rose to 357.4B yen, resulting in gross profit of 125.2B yen at a stable margin of 25.9%, unchanged from the prior period. However, SG&A expenses expanded significantly to 101.5B yen (21.0% of revenue), representing a material increase from the prior year's implied SG&A ratio. This cost base expansion drove operating income down 34.8% to 23.7B yen, compressing operating margin from 7.8% to 4.9%. Non-operating items contributed modestly negative with financial costs increasing alongside borrowing growth, leading to ordinary income of 22.2B yen, down 33.7% YoY. The gap between ordinary income (22.2B yen) and net income (16.8B yen) reflects a tax burden ratio of 73.0%, consistent with normal taxation without material extraordinary items. This represents a revenue up/profit down pattern, where modest sales growth was overwhelmed by operational cost expansion and resulting margin compression.
[Profitability] ROE of 4.9% declined from prior levels, driven by net profit margin compression to 3.5% (calculated as 16.8B yen net income divided by 482.6B yen revenue). Operating margin of 4.9% contracted 289 basis points from 7.8% in the prior year, reflecting SG&A expense growth outpacing revenue expansion. Gross profit margin held steady at 25.9%. [Cash Quality] Cash and deposits of 68.8B yen provide 0.25x coverage of short-term borrowings at 276.2B yen, indicating constrained liquidity. Working capital stands at 56.6B yen but is characterized by elevated receivables of 251.0B yen and inventories of 122.4B yen, suggesting extended operating cycles. [Investment Efficiency] Total asset turnover of 0.540x reflects moderate asset utilization, while ROIC estimated at approximately 3.0% indicates room for improvement in capital efficiency. [Financial Health] Equity ratio of 38.7% (346.6B yen equity against 894.5B yen total assets) and current ratio of 111.1% (566.4B yen current assets against 509.8B yen current liabilities) provide baseline financial stability, though debt-to-equity of 1.58x and concentration of 92.9% of interest-bearing debt in short-term maturities warrant monitoring.
Cash and deposits of 68.8B yen face pressure from elevated working capital requirements, with accounts receivable at 251.0B yen and inventories at 122.4B yen representing significant capital tied up in operations. Short-term borrowings increased 87.9B yen YoY to 276.2B yen, a 46.7% surge, indicating external financing to support working capital needs or operational requirements. The cash-to-short-term-debt ratio of 0.25x highlights immediate refinancing risk, as current cash holdings cover only one-quarter of near-term debt obligations. Long-term loans of 21.0B yen represent 7.1% of total interest-bearing debt, indicating heavy reliance on short-term funding. The expansion in current liabilities to 509.8B yen reflects both increased borrowings and trade payables, with electronically recorded obligations comprising 40.0B yen. Working capital efficiency shows strain with extended receivables and inventory turnover cycles, constraining organic cash generation despite positive operating profit.
Ordinary income of 22.2B yen versus operating income of 23.7B yen indicates net non-operating costs of approximately 1.5B yen, representing 0.3% of revenue. This modest gap primarily reflects financial costs associated with increased borrowing levels, as interest-bearing debt grew substantially during the period. Non-operating expense burden remains manageable with interest coverage ratio at 10.47x (operating income to interest expense), preserving debt servicing capacity despite margin pressure. The profit before tax of 23.1B yen compared to ordinary income of 22.2B yen shows minimal extraordinary items, confirming earnings derive from core operations. However, earnings quality faces headwinds from working capital deterioration, evidenced by accounts receivable at 190 days sales outstanding and inventory at 125 days, extending the cash conversion cycle. The combination of compressed operating margins, elevated working capital requirements, and increased short-term debt dependence suggests earnings quality warrants close monitoring for cash flow sustainability.
Full-year guidance projects revenue of 615.0B yen (YoY +1.5%), operating income of 34.0B yen (YoY -17.7%), ordinary income of 33.0B yen (YoY -12.7%), and net income of 23.0B yen. Q3 progress rates stand at revenue 78.5% (482.6B/615.0B), operating income 69.7% (23.7B/34.0B), and ordinary income 67.2% (22.2B/33.0B) of full-year targets. Revenue tracking slightly ahead of the standard 75% Q3 progress rate reflects seasonal patterns or steady quarterly execution. However, profit metrics lag expectations with operating income at 69.7% versus standard 75%, implying Q4 needs to deliver approximately 10.3B yen operating income, representing 43.5% of first three quarters combined, to achieve guidance. This back-end loading requires significant margin recovery through SG&A control or volume leverage in Q4. The company's maintained guidance suggests confidence in cost management initiatives or seasonal profit patterns in the final quarter.
Annual dividend is planned at 45.0 yen per share (interim 40.0 yen, year-end 42.0 yen), representing a payout ratio of approximately 46.0% based on current net income run-rate. The dividend per share compares to full-year EPS forecast of 269.24 yen, yielding a payout ratio of 16.7% on guidance basis, suggesting the company views current quarter earnings as below normalized levels. The payout ratio based on trailing net income of 16.8B yen indicates dividends are sustainable within operating cash flow constraints, though cash coverage should be monitored given elevated working capital needs and short-term debt obligations. No share buyback activity was disclosed in the period. The dividend policy maintains shareholder returns despite profit decline, signaling management confidence in earnings recovery and cash generation capacity to support both debt service and distributions.
Liquidity and refinancing risk: Short-term borrowings of 276.2B yen represent 92.9% of interest-bearing debt with cash coverage of only 0.25x, creating near-term maturity pressure. The 46.7% YoY increase in short-term borrowings alongside working capital expansion indicates potential cash flow strain requiring active credit facility management and rollover execution.
Working capital deterioration: Accounts receivable of 251.0B yen (approximately 190 days sales outstanding) and inventories of 122.4B yen (approximately 125 days) indicate extended operating cycles. Persistent working capital buildup constrains free cash flow generation and increases external financing dependence, with potential collection or obsolescence risks if market conditions soften.
Margin compression and cost control: Operating margin contracted 289 basis points to 4.9% as SG&A expenses grew faster than revenue, reducing profitability by 34.8% despite 3.4% sales growth. Continued cost base expansion without corresponding revenue acceleration would further pressure profitability and cash generation, challenging dividend sustainability and debt servicing capacity.
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates substantially stronger financial health and operational efficiency compared to pharmaceutical industry medians. Profitability metrics show significant outperformance with ROE of 4.9% versus industry median of -35.8%, operating margin of 4.9% versus -218.2%, and net profit margin of 3.5% versus -216.8%, reflecting profitable operations while many industry peers operate at losses. Financial health indicators also exceed benchmarks with equity ratio of 38.7% below but reasonable versus industry median of 67.8%, though the company carries higher leverage typical of distribution operations. Efficiency metrics reveal faster asset utilization with asset turnover of 0.54x substantially exceeding industry median of 0.17x, consistent with pharmaceutical wholesale business models versus R&D-intensive manufacturers. Working capital management shows receivables turnover of approximately 190 days compared to industry median of 151 days, indicating slightly extended collection cycles, while inventory turnover appears more efficient than the industry median of 282 days. The current ratio of 1.11x falls below the industry's highly liquid median of 6.62x, reflecting the company's wholesale distribution model with higher inventory and receivables turnover requirements versus asset-light pharmaceutical developers. Overall positioning indicates a fundamentally profitable wholesale distribution operation with solid execution relative to a pharmaceutical industry benchmark dominated by development-stage or specialty manufacturers with negative profitability profiles.
※ Industry: Pharmaceutical (13 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
Profitable growth trajectory despite margin pressure: The company maintains positive profitability with ROE of 4.9%, operating margin of 4.9%, and net margin of 3.5%, substantially outperforming pharmaceutical industry peers operating at median losses. Revenue growth of 3.4% YoY demonstrates market share stability, though the 34.8% operating income decline driven by SG&A expansion represents the critical management challenge requiring operational efficiency improvements in coming periods.
Liquidity management as key near-term focus: Short-term borrowings surged 46.7% to 276.2B yen with cash coverage of 0.25x, creating refinancing focus alongside working capital optimization needs. Extended receivables and inventory cycles tie up approximately 374B yen in operating assets, representing 77.5% of total assets, indicating significant cash flow improvement potential through collection acceleration and inventory efficiency gains that would reduce external financing dependence and strengthen balance sheet resilience.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.